Blueprint Medicines (BPMC) Stock Statistics & Valuation Metrics

Blueprint Medicines has a market cap or net worth of $6.40B. The enterprise value is ―.

Blueprint Medicines has 64,582,160 shares outstanding. The number of shares has decreased by -2.65% in one year.

Blueprint Medicines’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -22.43%.

The current PE Ratio of Blueprint Medicines is -81.72. Blueprint Medicines’s PEG ratio is 0.30.

In the last 12 months, Blueprint Medicines had revenue of 508.82M and earned -67.09M in profits. Earnings per share was -1.07.

In the last 12 months, operating cash flow was -145.55M and capital expenditures -5.36M, giving a free cash flow of -150.91M billion.

Blueprint Medicines pays an annual dividend of ―, resulting in a dividend yield of ―

Blueprint Medicines upcoming earnings date is Jul 30, 2025, TBA Not Confirmed.

Blueprint Medicines as a current ratio of 2.85, with Debt / Equity ratio of 35.88%

In the past 12 months, Blueprint Medicines has paid 1.23M in taxes.

Blueprint Medicines EV to EBITDA ratio is 304.12, with an EV/FCF ratio of -29.66.

Blueprint Medicines has $576.24M in cash and marketable securities with $122.75M in debt, giving a net cash position of -$453.49M billion.

Gross margin is 95.84%, with operating margin of -41.67%, and net profit margin of -13.19%.

The average price target for Blueprint Medicines is $127.94, which is 11.43% higher than the current price. The consensus rating is Strong Buy